IFRX
IFRX
NASDAQ · Biotechnology

Inflarx Nv

$0.89
+0.06 (+7.54%)
As of Mar 31, 10:12 PM ET ·
Financial Highlights (FY 2026)
Revenue
29.5K
Net Income
-50,002,178
Gross Margin
-24,678.8%
Profit Margin
-155,587.4%
Rev Growth
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -24,678.8% 28.8% 28.8% 28.8%
Operating Margin -164,539.4% -7.0% -6.8% -7.5%
Profit Margin -155,587.4% -7.4% -5.8% -6.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 29.5K 9.23M 9.01M 7.68M
Gross Profit -7,278,021 2.66M 2.60M 2.21M
Operating Income -48,524,329 -646,720 -609,627 -579,731
Net Income -50,002,178 -678,125 -522,642 -466,092
Gross Margin -24,678.8% 28.8% 28.8% 28.8%
Operating Margin -164,539.4% -7.0% -6.8% -7.5%
Profit Margin -155,587.4% -7.4% -5.8% -6.1%
Rev Growth +6.0% +24.9% +0.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 739.7K 6.26M 5.90M 6.22M
Total Equity 32.88M 27.81M 26.71M 29.49M
D/E Ratio 0.02 0.23 0.22 0.21
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -46,205,197 -963,511 -904,753 -762,039
Free Cash Flow -508,030 -465,093 -442,494